Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is expected to announce its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Summit Therapeutics Stock Down 2.1 %

Shares of NASDAQ:SMMT traded down $0.45 during trading on Friday, reaching $21.37. The stock had a trading volume of 2,355,147 shares, compared to its average volume of 2,311,432. Summit Therapeutics has a 52 week low of $2.10 and a 52 week high of $33.89. The firm has a market capitalization of $15.76 billion, a price-to-earnings ratio of -76.32 and a beta of -0.88. The stock has a fifty day simple moving average of $19.49 and a two-hundred day simple moving average of $18.48.

Analyst Upgrades and Downgrades

SMMT has been the topic of a number of research reports. JMP Securities initiated coverage on shares of Summit Therapeutics in a research report on Monday, November 4th. They set a "market outperform" rating and a $32.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Summit Therapeutics in a research note on Friday, December 6th. They issued a "buy" rating and a $31.00 target price on the stock. Truist Financial began coverage on shares of Summit Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $35.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $44.00 price target on shares of Summit Therapeutics in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company began coverage on shares of Summit Therapeutics in a research report on Wednesday, December 11th. They set an "overweight" rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $33.57.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.